Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis

European Respiratory Journal

Volumn 29, Issue 5, 2007, Pages 976-985

  Chaudhary, N I ^a   Roth, G J ^a   Hilberg, F ^b   Muller Quernheim J ^c   Prasse, A ^c   Zissel, G ^c   Schnapp, Andreas ^a   Park, J E ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

BIBF 1000; Bleomycin; Imatinib mesylate; Lung fibrosis

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ABELSON KINASE; BASIC FIBROBLAST GROWTH FACTOR; BIBF 1000; BLEOMYCIN; COLLAGEN; FIBROBLAST GROWTH FACTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; FIBROBLAST; GENE EXPRESSION; INHIBITION KINETICS; ISOLATED LUNG; LUNG FIBROSIS; MALE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; INDOLES; MALE; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PULMONARY FIBROSIS; PYRIMIDINES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34248177260     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00152106     Document Type: Article

References (65)

1. Dacic S, Yousem SA. Histologic classification of idiopathic chronic interstitial pneumonias. Am J Respir Cell Mol Biol 2003; 29: S5-S9.
2. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
3. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
4. Nadrous HF, Myers JL, Decker PA, Ryu JH. Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 2005; 80: 37-40.
5. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990; 3: 507-511.
6. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 1: 520-524.
7. Holgate ST, Lackie PM, Davies DE, Roche WR, Walls AF. The bronchial epithelium as a key regulator of airway inflammation and remodelling in asthma. Clin Exp Allergy 1999; 29: Suppl. 2, 90-95.
8. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: S28-S38.
9. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10: 927-939.
10. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
11. Uhal BD, Joshi I, True AL, et al. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 1995; 269: L819-L828.
12. Ramos C, Montano M, Garcia-Alvarez J, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001; 24: 591-598.
13. Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000; 105: 193-204.
14. Zhang S, Smartt H, Holgate ST, Roche WR. Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: an in vitro co-culture model of airway remodelling in asthma. Lab Invest 1999; 79: 395-405.
15. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004; 170: 242-251.
16. Crystal RG, Bitterman PB, Mossman B, et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002; 166: 236-246.
17. Fehrenbach H, Haase M, Kasper M, Koslowski R, Schuh D, Muller M. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis. Virchows Arch 1999; 435: 20-31.
18. Hamada N, Kuwano K, Yamada M, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005; 175: 1224-1231.
19. Hetzel M, Bachem M, Anders D, Trischler G, Faehling M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung 2005; 183: 225-237.
20. Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159: 1383-1395.
21. Krein PM, Winston BW. Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. Chest 2002; 122: 289S-293S.
22. Lappi-Blanco E, Soini Y, Kinnula V, Paakko P. VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. J Pathol 2002; 196: 220-227.
23. Lasky JA, Ortiz LA, Tonthat B, et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 1998; 275: L365-L371.
24. Masamune A, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. World J Gastroenterol 2005; 11: 6144-6151.
25. Ogata T, Miyauchi T, Irukayama-Tomobe Y, Takanashi M, Goto K, Yamaguchi I. The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin-1-induced cardiac fibroblast proliferation. J Cardiovasc Pharmacol 2004; 44: Suppl. 1, S279-S282.
26. Prasse A, Pechkovsky DV, Toews GB, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006; 173: 781-792.
27. Coker RK, Laurent GJ, Shahzeidi S, et al. Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol 1997; 150: 981-991.
28. McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ. The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim Biophys Acta 1991; 1091: 231-235.
29. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor{β}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005; 171: 889-898.
30. de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect 2006; 19: 85-90.
31. Tang B, Vu M, Booker T, et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003; 112: 1116-1124.
32. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12: 22-29.
33. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-273.
34. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201: 925-935.
35. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF - beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990; 63: 515-524.
36. Battegay EJ, Raines EW, Colbert T, Ross R. TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 1995; 154: 6040-6047.
37. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989; 243: 393-396.
38. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001; 107: 1529-1536.
39. Zhuo Y, Zhang J, Laboy M, Lasky JA. Modulation of PDGF-C and PDGF-D expression during bleomycininduced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2004; 286: L182-L188.
40. Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171: 1279-1285.
41. Chaudhary NI, Schnapp A, Park JE. Pharmacological differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173: 769-776.
42. Richter A, Puddicombe SM, Lordan JL, et al. The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001; 25: 385-391.
43. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001; 107: 295-301.
44. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963; 18: 225-237.
45. Bisping G, Kropff M, Werming D, et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. Blood 2005; 107: 2079-2089.
46. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF-)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002; 62: 58-64.
47. Yi ES, Lee H, Yin S, et al. Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol 1996; 149: 539-548.
48. 2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001; 163: 152-157.
49. Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 2003; 63: 7791-7798.
50. Li Y. Azuma A, Usuki J, et al. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF - beta signaling in lung fibroblasts. Respir Res 2006; 7: 16.
51. Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005; 125: 450-455.
52. Pittet JF, Griffiths MJ, Geiser T, et al. TGF - beta is a critical mediator of acute lung injury. J Clin Invest 2001; 107: 1537-1544.
53. Kishi K, Homma S, Kurosaki A, Motoi N, Yoshimura K. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr 2006; 30: 95-99.
54. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17: 1216-1219.
55. Chaudhary NI, Richter A, Roche WR, et al. The role of autocrine growth factor in the proliferation of asthmatic (myo)fibroblasts. Am J Respir Crit Care Med 2003; 165: A78.
56. Guyot C, Lepreux S, Combe C, et al. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006; 38: 135-151.
57. Qi W, Chen X, Poronnik P, Pollock CA. The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int J Biochem Cell Biol 2006; 38: 1-5.
58. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF - beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-1316.
59. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 2003; 162: 533-546.
60. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004; 15: 229-235.
61. Khalil N, Xu YD, O'Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 NMPK and JNK. J Biol Chem 2005; 280: 43000-43009.
62. Jones SG, Morrisey K, Williams JD, Phillips AO. TGF - beta1 stimulates the release of pre-formed bFGF from renal proximal tubular cells. Kidney Int 1999; 56: 83-91.
63. Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987; 84: 2292-2296.
64. Kilarski WW, Jura N, Gerwins P. An ex vivo model for functional studies of myofibroblasts. Lab Invest 2005; 85: 643-654.
65. Keane MP. Angiogenesis and pulmonary fibrosis: feast or famine? Am J Respir Crit Care Med 2004; 170: 207-209.